TriangleSL-401 (NCT03113643)
SL-401 trial for Acute Myeloid Leukemia (NCT03113643). This is a short film with English narration. The transcript is on this page, and the written brief is separate.
Lo que dice el vídeo
Lee la transcripción
Older adults with acute myeloid leukemia often get two drugs, azacitidine and venetoclax. Remissions come, but many fade, especially with a TP53 mutation.
The idea: add a third drug that carries a bacterial toxin straight into leukemia cells.
Tagraxofusp is interleukin-3, a growth signal these cells crave, fused to diphtheria toxin. Cells carrying the CD123 receptor pull it in and die. It is already approved for a rare leukemia. In the lab, azacitidine re-sensitized resistant cells and left them leaning on BCL-2, venetoclax's target.
In fifty-six adults, the triplet was tolerable; in untreated high-risk AML, sixty-nine percent responded, including half of those with TP53 mutations.
Andrew Lane leads it at Dana-Farber, with City of Hope and MD Anderson. Public record; not medical advice.
¿Ya estás en un ensayo?
Se convierte en un proyecto que hay que manejar: citas, estudios de imagen, análisis, efectos secundarios y papeleo. Triangle lo mantiene organizado en un solo lugar, para ti o para quien te ayuda.
Organizar mi ensayoPrueba gratuita de 7 días, después $9 al mes. Cancela cuando quieras.
Cómo funcionan estos ensayos: qué es de verdad la fase 1 · preguntas frecuentes No es evidencia clínica.